Long-Term Outcomes after Conversion to a Belatacept-Based Immunosuppression in Kidney Transplant Recipients.

Gillian Divard Olivier AubertCharlotte Debiais-DeschampMarc RaynaudValentin Goutaudier Marta SablikCaroline SayegChristophe LegendreJulie ObertDany AnglicheauCarmen LefaucheurAlexandre Loupy

Published in: Clinical journal of the American Society of Nephrology : CJASN (2024)

This study shows that conversion to belatacept post-transplant was associated with lower risk of graft failure and acceptable safety outcomes compared with patients maintained on CNI.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
prognostic factors
peritoneal dialysis
patient reported outcomes
weight loss